Cargando…

Clinical presentation and outcomes in children with retinoblastoma managed at the Uganda Cancer Institute

BACKGROUND: The majority of patients with retinoblastoma, the most common intraocular cancer of childhood, are found in low-and middle-income countries (LMICs), with leukocoria being the most common initial presenting sign and indication for referral. Findings from the current study serve to augment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalinaki, Abubakar, Muwonge, Haruna, Balagadde-Kambugu, Joyce, Mulumba, Yusuf, Ntende, Jacob, Ssali, Grace, Nakiyingi, Lydia, Nakanjako, Damalie, Nalukenge, Caroline, Ampaire, Anne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924608/
https://www.ncbi.nlm.nih.gov/pubmed/35308301
http://dx.doi.org/10.1155/2022/8817215
_version_ 1784669896042348544
author Kalinaki, Abubakar
Muwonge, Haruna
Balagadde-Kambugu, Joyce
Mulumba, Yusuf
Ntende, Jacob
Ssali, Grace
Nakiyingi, Lydia
Nakanjako, Damalie
Nalukenge, Caroline
Ampaire, Anne M.
author_facet Kalinaki, Abubakar
Muwonge, Haruna
Balagadde-Kambugu, Joyce
Mulumba, Yusuf
Ntende, Jacob
Ssali, Grace
Nakiyingi, Lydia
Nakanjako, Damalie
Nalukenge, Caroline
Ampaire, Anne M.
author_sort Kalinaki, Abubakar
collection PubMed
description BACKGROUND: The majority of patients with retinoblastoma, the most common intraocular cancer of childhood, are found in low-and middle-income countries (LMICs), with leukocoria being the most common initial presenting sign and indication for referral. Findings from the current study serve to augment earlier findings on the clinical presentation and outcomes of children with retinoblastoma in Uganda. METHODS: This was a retrospective study in which we reviewed records of children admitted with a diagnosis of retinoblastoma at the Uganda Cancer Institute from January 2009 to February 2020. From the electronic database, using admission numbers, files were retrieved. Patient information was recorded in a data extraction tool. RESULTS: A total of 90 retinoblastoma patients were studied, with a mean age at the first Uganda Cancer Institute (UCI) presentation of 36.7 months. There were more males (57.8%) than females, with a male to female ratio of 1.37 : 1. The majority (54.4%) had retinoblastoma treatment prior to UCI admission. The most common presenting symptoms were leukocoria (85.6%), eye reddening (64.4%), and eye swelling (63.3%). At 3 years of follow-up after index admission at UCI, 36.7% of the patients had died, 41.1% were alive, and 22.2% had been lost to follow-up. The median 3-year survival for children with retinoblastoma in our study was 2.18 years. Significant predictors of survival in the multivariate analysis were follow-up duration ([Formula: see text]), features of metastatic spread (P = 0.001), history of eye swelling (P = 0.012), and bilateral enucleation (P = 0.011). CONCLUSIONS: The majority of children who presented to the Uganda Cancer Institute were referred with advanced retinoblastoma, and there was a high mortality rate. Retinoblastoma management requires a multidisciplinary team that should include paediatric ophthalmologists, paediatric oncologists, ocular oncologists, radiation oncologists, and nurses.
format Online
Article
Text
id pubmed-8924608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89246082022-03-17 Clinical presentation and outcomes in children with retinoblastoma managed at the Uganda Cancer Institute Kalinaki, Abubakar Muwonge, Haruna Balagadde-Kambugu, Joyce Mulumba, Yusuf Ntende, Jacob Ssali, Grace Nakiyingi, Lydia Nakanjako, Damalie Nalukenge, Caroline Ampaire, Anne M. J Cancer Epidemiol Research Article BACKGROUND: The majority of patients with retinoblastoma, the most common intraocular cancer of childhood, are found in low-and middle-income countries (LMICs), with leukocoria being the most common initial presenting sign and indication for referral. Findings from the current study serve to augment earlier findings on the clinical presentation and outcomes of children with retinoblastoma in Uganda. METHODS: This was a retrospective study in which we reviewed records of children admitted with a diagnosis of retinoblastoma at the Uganda Cancer Institute from January 2009 to February 2020. From the electronic database, using admission numbers, files were retrieved. Patient information was recorded in a data extraction tool. RESULTS: A total of 90 retinoblastoma patients were studied, with a mean age at the first Uganda Cancer Institute (UCI) presentation of 36.7 months. There were more males (57.8%) than females, with a male to female ratio of 1.37 : 1. The majority (54.4%) had retinoblastoma treatment prior to UCI admission. The most common presenting symptoms were leukocoria (85.6%), eye reddening (64.4%), and eye swelling (63.3%). At 3 years of follow-up after index admission at UCI, 36.7% of the patients had died, 41.1% were alive, and 22.2% had been lost to follow-up. The median 3-year survival for children with retinoblastoma in our study was 2.18 years. Significant predictors of survival in the multivariate analysis were follow-up duration ([Formula: see text]), features of metastatic spread (P = 0.001), history of eye swelling (P = 0.012), and bilateral enucleation (P = 0.011). CONCLUSIONS: The majority of children who presented to the Uganda Cancer Institute were referred with advanced retinoblastoma, and there was a high mortality rate. Retinoblastoma management requires a multidisciplinary team that should include paediatric ophthalmologists, paediatric oncologists, ocular oncologists, radiation oncologists, and nurses. Hindawi 2022-03-08 /pmc/articles/PMC8924608/ /pubmed/35308301 http://dx.doi.org/10.1155/2022/8817215 Text en Copyright © 2022 Abubakar Kalinaki et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kalinaki, Abubakar
Muwonge, Haruna
Balagadde-Kambugu, Joyce
Mulumba, Yusuf
Ntende, Jacob
Ssali, Grace
Nakiyingi, Lydia
Nakanjako, Damalie
Nalukenge, Caroline
Ampaire, Anne M.
Clinical presentation and outcomes in children with retinoblastoma managed at the Uganda Cancer Institute
title Clinical presentation and outcomes in children with retinoblastoma managed at the Uganda Cancer Institute
title_full Clinical presentation and outcomes in children with retinoblastoma managed at the Uganda Cancer Institute
title_fullStr Clinical presentation and outcomes in children with retinoblastoma managed at the Uganda Cancer Institute
title_full_unstemmed Clinical presentation and outcomes in children with retinoblastoma managed at the Uganda Cancer Institute
title_short Clinical presentation and outcomes in children with retinoblastoma managed at the Uganda Cancer Institute
title_sort clinical presentation and outcomes in children with retinoblastoma managed at the uganda cancer institute
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924608/
https://www.ncbi.nlm.nih.gov/pubmed/35308301
http://dx.doi.org/10.1155/2022/8817215
work_keys_str_mv AT kalinakiabubakar clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT muwongeharuna clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT balagaddekambugujoyce clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT mulumbayusuf clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT ntendejacob clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT ssaligrace clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT nakiyingilydia clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT nakanjakodamalie clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT nalukengecaroline clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute
AT ampaireannem clinicalpresentationandoutcomesinchildrenwithretinoblastomamanagedattheugandacancerinstitute